Skip to main content
Download PDF

Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice

BMC Pregnancy and Childbirth volume 22, Article number: 503 (2022) Cite this article

Abstract

Background

One of every four preterm neonates is born to a woman with sterile intra-amniotic inflammation (inflammatory process induced by alarmins); yet, this clinical condition still lacks treatment. Herein, we utilized an established murine model of sterile intra-amniotic inflammation induced by the alarmin high-mobility group box-1 (HMGB1) to evaluate whether treatment with clarithromycin prevents preterm birth and adverse neonatal outcomes by dampening maternal and fetal inflammatory responses.

Methods

Pregnant mice were intra-amniotically injected with HMGB1 under ultrasound guidance and treated with clarithromycin or vehicle control, and pregnancy and neonatal outcomes were recorded (n = 15 dams each). Additionally, amniotic fluid, placenta, uterine decidua, cervix, and fetal tissues were collected prior to preterm birth for determination of the inflammatory status (n = 7–8 dams each).

Results

Clarithromycin extended the gestational length, reduced the rate of preterm birth, and improved neonatal mortality induced by HMGB1. Clarithromycin prevented preterm birth by interfering with the common cascade of parturition as evidenced by dysregulated expression of contractility-associated proteins and inflammatory mediators in the intra-uterine tissues. Notably, clarithromycin improved neonatal survival by dampening inflammation in the placenta as well as in the fetal lung, intestine, liver, and spleen.

Conclusions

Clarithromycin prevents preterm birth and improves neonatal survival in an animal model of sterile intra-amniotic inflammation, demonstrating the potential utility of this macrolide for treating women with this clinical condition, which currently lacks a therapeutic intervention.

Peer Review reports

Background

Preterm birth is the leading cause of neonatal morbidity and mortality worldwide [1,2,3], with two-thirds of all cases preceded by spontaneous preterm labor [4]. The latter is a syndrome comprising multiple etiologies [4, 5], with intra-amniotic infection and/or inflammation as the only well-established causal link to preterm birth [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21]. Intra-amniotic inflammation was thought to be exclusively initiated by the invasion of microbes into the amniotic cavity (i.e., intra-amniotic infection) [22,23,24,25]. Yet, the advancement of molecular microbiological techniques has allowed for the discovery of a new entity, sterile intra-amniotic inflammation, in which elevated concentrations of cytokines [i.e., interleukin (IL)-6] occur in the absence of detectable microorganisms [26,27,28,29,30]. From an immunological perspective, sterile inflammation is triggered by danger signals or damage-associated molecular patterns (DAMPs; also known as alarmins) released upon cellular stress, senescence, or necrosis [31,32,33,34]. Therefore, we have proposed that elevated concentrations of alarmins in the amniotic cavity are responsible for activating the inflammatory cascade leading to preterm labor and birth [27, 35]. In support of this concept, the concentrations of several classical alarmins, namely high-mobility group box-1 (HMGB1) [27, 36], S100 calcium-binding protein-B (S100B) [37], IL-1α [38, 39], and heat-shock protein 70 (HSP70) [40], are increased in women with intra-amniotic inflammation. Notably, sterile intra-amniotic inflammation is more prevalent than intra-amniotic infection in women with preterm labor and intact membranes [27]. In addition, patients with both sterile intra-amniotic inflammation and an increased amniotic fluid concentration of HMGB1 deliver sooner than those with a lower concentration of this alarmin [27], indicating that HMGB1 can serve as a predictor of preterm delivery. Indeed, we have mechanistically demonstrated that elevated concentrations of HMGB1 [10, 17], as well as other alarmins [14, 16, 21, 41], in the amniotic cavity induce sterile inflammation and cause preterm labor and birth. Therefore, we are actively engaged in finding strategies to prevent preterm labor and birth by inhibiting sterile intra-amniotic inflammation.

The mechanisms that lead to sterile intra-amniotic inflammation involve the activation of inflammatory pathways such as the NLR family pyrin domain-containing-3 (NLRP3) inflammasome [14, 16, 21, 42,43,44]. Hence, we have proposed the use of inhibitors of NLRP3 inflammasome activation to treat sterile intra-amniotic inflammation and to prevent preterm labor and birth [14]. However, a limitation of this approach is that a few cases of spontaneous preterm labor categorized as sterile intra-amniotic inflammation may be associated with undetectable microorganisms, thus the blockade of the NLRP3 inflammasome could limit the host response mechanisms required for clearance of such a pathogen. Alternatively, we have recently shown that treatment with betamethasone, a widely used corticosteroid, prevents preterm birth; nevertheless, such an approach did not rescue neonatal mortality induced by the intra-amniotic administration of HMGB1 [17]. Therefore, a strategy that not only prevents preterm birth but also improves neonatal survival by dampening the intra-amniotic inflammatory response induced by alarmins is urgently needed.

Recent studies have shown that specific antibiotics, such as clarithromycin, not only display effective anti-microbial properties in women with intra-amniotic infection but also exert anti-inflammatory effects in the amniotic cavity [45,46,47,48,49]. Therefore, we propose that clarithromycin, which is already approved for clinical use in pregnant women, could represent a viable treatment for women presenting with sterile intra-amniotic inflammation and risk of preterm delivery. Importantly, clarithromycin is the macrolide that most efficiently crosses the placenta [50, 51]. Indeed, a recent clinical investigation showed a reduction in the severity of the intra-amniotic inflammatory response (as indicated by amniotic fluid IL-6 levels) in women who received treatment with clarithromycin [48]. However, to date, there has been no mechanistic demonstration showing that treatment with clarithromycin prevents preterm birth and adverse neonatal outcomes. Furthermore, the anti-inflammatory effects exerted by clarithromycin in the maternal–fetal tissues have not been investigated.

In the current study, we utilized an established model of sterile intra-amniotic inflammation induced by the alarmin HMGB1 to evaluate whether treatment with clarithromycin prevents preterm birth and adverse neonatal outcomes. Moreover, we investigated the maternal and fetal inflammatory responses in mice treated with clarithromycin to elucidate the anti-inflammatory effects of this macrolide in the setting of sterile intra-amniotic inflammation.

Methods

Mice

C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred in the animal care facility at the C.S. Mott Center for Human Growth and Development at Wayne State University (Detroit, MI, USA), according to protocols previously established by our group [12,13,14,15,16,17, 52,53,54,55]. Briefly, mice were housed with a 12 h light:12 h dark cycle (lights on from 6 am – 6 pm). Females of 8–12 weeks old were bred with males of proven fertility and checked daily between 8:00–9:00 a.m. for the appearance of a vaginal plug, which was considered as 0.5 day post coitum (dpc). After observing a vaginal plug, females were separated from the males and monitored daily, with a weight gain of at least 2 g by 12.5 dpc indicating pregnancy. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Wayne State University (Protocol No. 18–03-0584 and 21–04-3506). All animals were randomly assigned to experimental or control groups prior to the following experiments. Due to randomization, investigators were not blinded to group assignment.

Intra-amniotic administration of HMGB1

The intra-amniotic administration of HMGB1 was performed as previously described [10, 17]. Briefly, dams were anesthetized on the morning of 14.5 dpc (8:00 – 10:00 am) by inhalation of 2% isoflurane [Fluriso™ (Isoflurane, USP) Vetone Boise, ID, USA] and 1–2 L/min of oxygen in an induction chamber, and a mixture of 1.5–2% isoflurane and 1.5–2 L/min of oxygen was used to maintain anesthesia. Mice were positioned on a heating pad and stabilized with adhesive tape, and fur was removed from the abdomen and thorax using Nair cream (Church & Dwight Co., Inc., Ewing, NJ, USA). Body temperature was detected with a rectal probe (VisualSonics, Toronto, ON, Canada) throughout the procedure, and respiratory and heart rates were monitored by electrodes embedded in the heating pad. An ultrasound probe was fixed and mobilized with a mechanical holder, and the transducer was slowly moved toward the abdomen [56]. The ultrasound-guided intra-amniotic injection of recombinant human HMGB1 (n = 30; Biolegend, San Diego, CA, USA) at a concentration of 9 ng dissolved in 100 μL of sterile 1X phosphate-buffered saline (PBS; Life Technologies, Grand Island, NY, USA) was performed in each amniotic sac using a 30G needle (BD PrecisionGlide Needle; Becton Dickinson, Franklin Lakes, NJ, USA) [10]. This dose of HMGB1 was determined from the pathophysiological amniotic fluid concentrations found in women with sterile intra-amniotic inflammation [27]. Successful intra-amniotic injection was verified by using color Doppler ultrasound to identify the “injection jet sign” [17] (Fig. 1A). After ultrasound completion, mice were placed under a heat lamp for recovery, which was defined as when the mouse resumed normal activities, such as walking and responding, and typically occurred within 10 min after removal from anesthesia. After recovery, dams were monitored via video camera to observe pregnancy and neonatal outcomes.

Fig. 1
figure 1

Clarithromycin prevents preterm birth and improves neonatal survival induced by intra-amniotic injection of HMGB1. A Dams were intra-amniotically injected with HMGB1 in each sac under ultrasound guidance on 14.5 days post coitum (dpc) and treated with 75 mg/kg of clarithromycin (CLR; n = 15) or DMSO (vehicle control; n = 15) at 6, 12, 24, 48, 72, and 96 h post-injection. Dams were monitored until delivery, and neonates were followed until three weeks of age. B Gestational length (dpc) of dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-value was determined using the one-sided Mann–Whitney U-test. C Rate of preterm birth of dams intra-amniotically injected with HMGB1 and treated with CLR (blue bar plot) or DMSO (red bar plot). P-value was determined using the one-sided Fisher’s exact test. D Kaplan–Meier survival curve showing the percentage of surviving neonates at 1, 2, and 3 weeks of age from dams intra-amniotically injected with HMGB1 and treated with CLR (blue line) or DMSO (red line). P-value was determined using the Mantel-Cox test. E–G Neonatal weights per litter at 1, 2, and 3 weeks of age from dams intra-amniotically injected with HMGB1 and treated with CLR [blue dots, 2–6 (mean = 3.8) neonates/litter] or DMSO [red dots, 1–2 (mean = 1.5) neonates/dam]. Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-value was determined using the one-sided Mann–Whitney U-test

Full size image

Clarithromycin treatment of mice intra-amniotically injected with HMGB1

After the ultrasound-guided intra-amniotic injection of HMGB1, dams were randomized to receive subcutaneous treatment with either 75 mg/kg of clarithromycin (n = 15; Sigma-Aldrich, St. Louis, MO, USA) or its vehicle control [n = 15; diluted dimethyl sulfoxide (DMSO), Sigma-Aldrich] at 6, 12, 24, 48, 72, and 96 h post-intra-amniotic injection. Clarithromycin (reconstituted with DMSO) and DMSO (vehicle control) were diluted in sterile 5% dextrose water. Dams were continuously observed between each treatment via video camera to evaluate pregnancy and neonatal outcomes. The dose of clarithromycin was determined based on a previous study [57], suggesting that a 75 mg/kg/day dose of clarithromycin in mice was equivalent to human oral clarithromycin dosages (ranging from 250 mg twice daily to 500 mg twice daily in adults [58]). The latter dose has been demonstrated to ameliorate intra-amniotic infection or inflammation in a subset of women with preterm labor and intact membranes [47], cervical insufficiency [46], or preterm prelabor rupture of the membranes [45] when it is administered together with other antibiotics (ceftriaxone and metronidazole) or alone [48]. Moreover, Ureaplasma parvum-induced preterm birth and adverse neonatal outcomes were shown to improve after treatment with the same dose of clarithromycin in mice [15].

Video monitoring of pregnancy and neonatal outcomes

Experimental mice were continuously monitored with a video camera (Sony Corporation, Tokyo, Japan) to record pregnancy outcomes, using observational protocols established by our group [12, 14,15,16,17, 52,53,54,55]. Primary measured outcomes included the rates of preterm birth and neonatal mortality. Gestational length was calculated for each dam as the elapsed time from the presence of the vaginal plug until the appearance of the first pup in the cage bedding. Preterm birth, defined as delivery occurring before 19.0 dpc, was calculated as the proportion of females delivering prior to 19.0 dpc among the total number of mice per study group [17]. Late preterm birth was defined as delivery occurring between 18.0 and 19.0 dpc [17]. The rate of neonatal mortality was calculated for each litter as the proportion of delivered pups found dead among the total litter size. A total of 45 neonates born to control dams and 55 neonates born to dams treated with clarithromycin were observed daily until three weeks postpartum to evaluate neonatal weight and survival. Neonates found dead within the first week of life were excluded from comparisons of neonatal weight per litter.

Tissue sampling from dams intra-amniotically injected with HMGB1

Pregnant mice were intra-amniotically injected with HMGB1 under ultrasound guidance on 14.5 dpc. Dams were then treated with either 75 mg/kg of clarithromycin (n = 7) or DMSO (n = 8) at 6, 12, 24, 48, 72, and 96 h post-intra-amniotic injection as described above. On 18.5 dpc, two hours after the last dose of clarithromycin or DMSO (i.e., 98 h post-HMGB1 injection), mice were euthanized by exsanguination (under anesthesia), and tissue collection was performed to obtain the decidua, uterus, cervix, fetal membranes, placenta, fetal lung, fetal intestine, fetal liver, and fetal spleen. Briefly, tissues were either snap-frozen in liquid nitrogen and stored at -80 °C or submerged in RNAlater solution (Invitrogen/Thermo Fisher Scientific, Baltics UAB, Vilnius, Lithuania). Amniotic fluid was collected from each amniotic sac using a 26G needle. Amniotic fluid samples were centrifuged at 1,300 × g for 10 min at 4 °C, after which the supernatants were separated and kept at -20 °C until analysis.

RNA isolation, cDNA synthesis, and reverse transcription-quantitative PCR analysis of murine tissues

Total RNA was isolated from the decidua, uterus, cervix, fetal membranes, placenta, fetal lung, fetal intestine, fetal liver, and fetal spleen using QIAshredders, RNase-free DNase sets, and RNeasy Mini kits (all from Qiagen, Hilden, Germany), according to the manufacturer’s instructions, as previously described [15]. The concentrations and integrity of RNA were determined using the Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA). Complementary (c)DNA was synthesized by using SuperScript IV VILO Master Mix (Invitrogen/Thermo Fisher Scientific). Gene expression profiling was carried out on the BioMark system (Fluidigm, San Francisco, CA, USA) with TaqMan gene expression assays (Applied Biosystems/Life Technologies Corporation, Pleasanton, CA, USA) listed in Additional file 2 and Table S1. The expression of multiple reference genes (Gusb, Hsp90ab1, Gapdh, and Actb) was averaged within each sample to determine the negative delta threshold cycle (-∆CT) values.

Determination of cytokine concentrations in amniotic fluid

Amniotic fluid samples were assessed for cytokine/chemokine concentrations using the ProcartaPlex mouse cytokine and chemokine panel 1A 36-plex (Invitrogen/Thermo Fisher Scientific), according to the manufacturer’s instructions. For this study, we only report the amniotic fluid concentrations of IL-6, IL-1β, TNF, IL-1α, IL-10, IFNγ, M-CSF, CCL2 (MCP-1), CCL4 (MIP-1α), CCL5 (RANTES), CXCL1 (GRO-α), and CXCL10 (IP-10), as they have been shown to be involved in intra-amniotic inflammation [39]. The rest of the cytokines included in the assay did not differ between study groups, thus were not shown. Plates were read by using the Luminex FLEXMAP 3D (Luminex, Austin, TX, USA) and analyte concentrations were calculated with the Xponent version 4.2 (Luminex). The sensitivities of the assays were as follows: 0.21 pg/mL (IL-6), 0.14 pg/mL (IL-1β), 0.39 pg/mL (TNF), 0.32 pg/mL (IL-1α), 0.69 pg/mL (IL-10), 0.09 pg/mL (IFNγ), 0.02 pg/mL (M-CSF), 3.43 pg/mL (CCL2/MCP-1), 1.16 pg/mL (CCL4/MIP-1β), 0.35 pg/mL (CCL5/RANTES), 0.05 pg/mL (CXCL1/GRO-α), and 0.26 pg/mL (CXCL10/IP-10).

Statistical analysis

Statistical analyses were conducted using GraphPad Prism version 8.0.1 for Windows (GraphPad Software, San Diego, California, USA, www.graphpad.com), as previously described [17]. A one-sided Fisher’s exact test was used to compare the rates of preterm birth, and a one-sided Mann–Whitney U-test was used to compare gestational length, neonatal mortality, neonatal weight, amniotic fluid cytokine/chemokine concentrations, and gene expression between study groups. Kaplan–Meier survival curves were used to plot and compare neonatal survival using the Mantel–Cox test. A p-value ≤ 0.05 was considered statistically significant.

Results

Treatment with clarithromycin prevents intra-amniotic HMGB1-induced preterm birth and neonatal mortality

We have previously demonstrated a causal relationship between the intra-amniotic injection of HMGB1 and preterm birth in mice [10, 17]. Indeed, we reported that 40% of dams that received intra-amniotic HMGB1 underwent late preterm delivery, resembling the clinical setting in which most preterm deliveries occur after 34 weeks of gestation (i.e., late preterm) [2, 5]. Clarithromycin has emerged as a potential treatment for women presenting with intra-amniotic inflammation and preterm labor [47]; therefore, we first evaluated whether treatment with clarithromycin improves adverse pregnancy and neonatal outcomes in the context of sterile intra-amniotic inflammation induced by HMGB1 (Fig. 1A). The gestational length of dams that received HMGB1 was extended by treatment with clarithromycin compared to that of dams that received HMGB1 and were treated with vehicle control (Fig. 1B). Importantly, 6/7 of the control mice underwent late preterm birth, while only 1/7 underwent early preterm birth (Fig. 1B), which is consistent with our previous report [17]. The extension of the gestational length was reflected by the rate of preterm birth, which was reduced by 33% [from 46.7% (7/15) to 13.3% (2/15)] after treatment with clarithromycin (Fig. 1C). Thus, clarithromycin can ameliorate HMGB1-induced preterm labor and birth.

A major consequence of prematurity is the increased risk of neonatal morbidity and mortality [1, 2, 59], a risk that is exacerbated in the context of intra-amniotic inflammation [24, 60,61,62,63,64]. Therefore, we next evaluated the outcomes of neonates born to dams that received intra-amniotic HMGB1 and were treated with clarithromycin. A greater proportion of neonates born to dams that received HMGB1 and clarithromycin survived up to three weeks of age compared to those born to control dams (Fig. 1D). No differences in litter weight at one (Fig. 1E), two (Fig. 1F), or three (Fig. 1G) weeks of age were found between neonates born to dams that received an intra-amniotic injection of HMGB1 with clarithromycin treatment and those that received vehicle control.

Together, these results demonstrate that clarithromycin can prevent preterm birth and, more importantly, improve neonatal survival in dams with sterile intra-amniotic inflammation induced by the intra-amniotic injection of HMGB1.

Clarithromycin prevents preterm labor and birth by interfering with the common pathway of parturition

Labor is a tightly regulated inflammatory process that requires the orchestrated activation of a common pathway including uterine contractility, cervical dilation, and decidual/fetal membrane activation [4, 65, 66]. Given that clarithromycin improved pregnancy outcomes in our model of HMGB1-induced preterm birth, we further investigated whether this beneficial effect was due to the effect of clarithromycin on the common pathway of labor (Fig. 2A). The uterine expression of Oxtr, a key regulator of uterine contraction [67], and the inflammatory genes Il1a, Il1b, and Ifng was reduced in dams intra-amniotically injected with HMGB1 and treated with clarithromycin compared to controls (Fig. 2B-E and Additional file 1). In the cervix, the expression of two crucial transcripts involved in cervical contraction and ripening, Gja1 [68] and Mmp9 [52, 69], respectively, was decreased upon treatment with clarithromycin (Fig. 2F&G and Additional file 1). Furthermore, the expression of the pro-inflammatory mediators Nfkb2 and Casp11 was decreased in the fetal membranes of dams injected with HMGB1 and treated with clarithromycin (Fig. 2H&I and Additional file 1). Decidual activation during labor involves the expression of multiple pro-inflammatory mediators [70,71,72,73,74,75,76,77,78], and we observed that treatment with clarithromycin had a potent anti-inflammatory effect in this tissue as indicated by the reduced expression of Il1a, Il12b, and Ccl22 together with increased expression of the anti-inflammatory cytokine Il10 (Fig. 2J-M and Additional file 1). Furthermore, the expression of the labor mediators Ptgs2 [79,80,81,82] and Oxtr [67] was reduced in the decidua upon treatment with clarithromycin (Fig. 2N&O and Additional file 1). Together, these data show that clarithromycin exerts anti-inflammatory effects in the intrauterine tissues implicated in the common pathway of parturition, representing a potential mechanism whereby this antibiotic prevents alarmin-induced preterm birth.

Fig. 2
figure 2

Clarithromycin interferes with the common pathway of labor. A Dams were intra-amniotically injected with HMGB1 under ultrasound guidance on 14.5 days post coitum (dpc) and treated with 75 mg/kg of clarithromycin (CLR; n = 7) or DMSO (vehicle control; n = 8) at 6, 12, 24, 48, 72, and 96 h post-injection. On 18.5 dpc, two hours after the last dose of CLR or DMSO, mice were euthanized and tissue collection was performed to obtain the decidua, uterus, cervix, fetal membranes, placenta, fetal lung, fetal intestine, fetal liver, and fetal spleen. Expression (-ΔCT) of B Oxtr, C Il1a, D Il1b, and E Ifng in the uteri of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of F Gja1 and G Mmp9 in the cervices of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of H Nfkb2 and I Casp11 in the fetal membranes of neonates born to HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of J Il1a, K Il12b, L Ccl22, M Il10, N Ptgs2, and O Oxtr in the decidua of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test 

Full size image

Clarithromycin does not reduce HMGB1-induced cytokine concentrations in the amniotic cavity

Next, we evaluated whether treatment with clarithromycin improved adverse perinatal outcomes by reducing the inflammatory milieu induced by HMGB1 in the amniotic cavity. Amniotic fluid was collected from dams intra-amniotically injected with HMGB1 and treated with clarithromycin or vehicle control, and a multiplex immunoassay was performed to assess the concentrations of multiple cytokines (Fig. 3A). There were no significant differences in the amniotic fluid concentrations of all evaluated cytokines between dams receiving HMGB1 and treated with clarithromycin and those that received vehicle control (Fig. 3B-M). These data suggest that the improved neonatal outcomes induced by clarithromycin treatment are not solely explained by decreased concentrations of pro-inflammatory cytokines in the amniotic cavity.

Fig. 3
figure 3

Clarithromycin does not alter HMGB1-induced cytokine concentrations in amniotic fluid. A Dams were intra-amniotically injected with HMGB1 under ultrasound guidance on 14.5 days post coitum (dpc) and treated with 75 mg/kg of clarithromycin (CLR; n = 7) or DMSO (vehicle control; n = 8) at 6, 12, 24, 48, 72, and 96 h post-injection. On 18.5 dpc, two hours after the last dose of CLR or DMSO, mice were euthanized and collection of amniotic fluid was performed to assess the concentrations of cytokines in the amniotic cavity. Amniotic fluid cytokine levels (pg/mL) of B IL-6, C IL-1β, D TNF, E IL-1α, F IL-10, G IFNγ, H M-CSF, I CCL2, J CCL4, K CCL5, L CXCL1, and M CXCL10 from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test

Full size image

Clarithromycin has potent anti-inflammatory effects in the placenta

Pregnant women with intra-amniotic inflammation are at increased risk of acute inflammatory lesions in the placenta [83]. Such lesions are associated with a high risk of both short- and long-term neonatal adverse outcomes including respiratory and intestinal pathologies [84,85,86]. Therefore, we sought to evaluate the effects of clarithromycin in the placentas of dams that received HMGB1. Placentas from dams intra-amniotically injected with HMGB1 and treated with clarithromycin or vehicle control were collected and the expression of inflammatory genes was evaluated (Fig. 4A). Importantly, the placental expression of Il6 and Tnf, both of which play a critical role in the inflammatory process of parturition [61, 87,88,89], was downregulated by treatment with clarithromycin compared to control dams (Fig. 4B&C and Additional file 1). Moreover, multiple transcripts for inflammatory cytokines and chemokines, including Il12b, Ccl3, Ccl5, Ccl22, Cxcl9, Cxcl10, Tlr9, and Nod1, were also downregulated in the placentas of dams that received intra-amniotic HMGB1 and were treated with clarithromycin (Fig. 4D-K and Additional file 1). These data suggest that clarithromycin reduces the placental inflammation induced by intra-amniotic HMGB1, providing a potential mechanism whereby this macrolide improves neonatal survival.

Fig. 4
figure 4

Clarithromycin downregulates inflammatory gene expression in the placenta. A Dams were intra-amniotically injected with HMGB1 under ultrasound guidance on 14.5 days post coitum (dpc) and treated with 75 mg/kg of clarithromycin (CLR; n = 7) or DMSO (vehicle control; n = 8) at 6, 12, 24, 48, 72, and 96 h post-injection. On 18.5 dpc, two hours after the last dose of CLR or DMSO, mice were euthanized and tissue collection was performed to obtain the placenta and assess inflammatory gene expression. Expression (-ΔCT) of B Il6, C Tnf, D Il12b, E Ccl3, F Ccl5, G Ccl22, H Cxcl9, I Cxcl10, J Tlr9, and K Nod1 from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test

Full size image

Clarithromycin ameliorates inflammation in the fetal tissues

The most common pathology in preterm neonates is respiratory distress syndrome [90, 91], while one of the most devastating pathologies associated with prematurity is necrotizing enterocolitis [92]. Thus, we next investigated the effects of maternal clarithromycin treatment in the lung and intestine of fetuses exposed to intra-amniotic HMGB1. The lung and intestine of fetuses from dams injected with HMGB1 and treated with clarithromycin or vehicle control were collected prior to delivery to evaluate the expression of inflammatory mediators (Fig. 4A). We found that the expression of Tnf and Il12b was downregulated in the fetal lung from dams exposed to HMGB1 and treated with clarithromycin compared to those born to vehicle control dams (Fig. 5A&B and Additional file 1). Moreover, clarithromycin treatment downregulated the expression of multiple inflammatory mediators such as Nfkb2, Ifng, Ccl5, Cxcl9, Tlr4, and Tlr9 in the intestine of fetuses exposed to HMGB1 (Fig. 5C-H and Additional file 1).

Fig. 5
figure 5

Clarithromycin downregulates inflammatory gene expression in the fetal lung and intestine. Expression (-ΔCT) of A Tnf and B Il12b in the lungs of fetuses from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of C Nfkb2, D Ifng, E Ccl5, F Cxcl9, G Tlr4, and H Tlr9 in the intestines of fetuses from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test

Full size image

The liver is the most important metabolic organ [93]. During fetal life, the liver plays an important role in hematopoiesis and protein synthesis [94, 95]. On the other hand, the spleen is the largest secondary lymphatic organ [96] and is critical for fetal adaptive immunity [97, 98]. Therefore, we evaluated whether maternal clarithromycin treatment modulates the expression of inflammatory mediators in such fetal organs. The liver and spleen were also collected prior to delivery from fetuses of dams intra-amniotically injected with HMGB1 that received clarithromycin or vehicle control (Fig. 4A). The fetal liver from dams treated with clarithromycin displayed downregulated expression of multiple pro-inflammatory immune mediators such as Il1a, Tnf, Il12b, Casp1, Casp11, Nod1, Ccl5, Ccl22, Cxcl9, Cxcl10, and Tlr9 compared to that of fetuses born to vehicle control dams (Fig. 6A-K and Additional file 1). Similarly, the expression of multiple inflammatory mediators, including Nfkb2, Il6, Il1a, Il18, Ccl22, Nod1, and Tlr9, was downregulated in the fetal spleen from dams that were exposed to HMGB1 and received clarithromycin (Fig. 6L-R and Additional file 1).

Fig. 6
figure 6

Clarithromycin downregulates inflammatory gene expression in the fetal liver and spleen. Expression (-ΔCT) of A Il1a, B Tnf, C Il12b, D Casp1, E Casp11, F Nod1, G Ccl5, H Ccl22, I Cxcl9, J Cxcl10, and K Tlr9 in the livers of fetuses from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of L Nfkb2, M Il6, N Il1a, O Il18, P Ccl22, Q Nod1, and R Tlr9 in the spleens of fetuses from dams intra-amniotically injected with HMGB1 and treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test

Full size image

Collectively, these findings indicate that clarithromycin acts as a modulator of the inflammatory response in fetuses exposed to HMGB1, which may contribute to the improved neonatal outcomes observed after treatment with this antibiotic.

Discussion

One of every four premature neonates is born to a woman with intra-amniotic inflammation [27, 99, 100], which was largely attributed to cultivable and non-cultivable microbes invading the amniotic cavity (i.e., infection) [22, 25,26,27,28,29]. Therefore, much research has been focused on exploring the appropriate antibiotic regimen for treating intra-amniotic infection [45,46,47,48,49]. Such efforts have been fruitful by demonstrating that the correct antibiotics (including clarithromycin) can eradicate intra-amniotic infection [45,46,47,48,49, 101], reduce intra-amniotic inflammation [45,46,47,48,49], and, more importantly, extend gestational length and prevent adverse neonatal outcomes, including intra-ventricular hemorrhage, peri-ventricular leukomalacia, and cerebral palsy [102]. Yet, recent research has provided solid evidence that intra-amniotic inflammation can occur in the absence of detectable and cultivable bacteria (i.e., sterile intra-amniotic inflammation) [26,27,28,29]. In such a setting, we have proposed that the optimal treatment strategy includes the utilization of drugs with anti-inflammatory properties [14, 17, 103], including antibiotics [45,46,47,48]. Indeed, a recent report showed that the macrolide clarithromycin can be used to treat women with sterile intra-amniotic inflammation who were destined to deliver preterm [48]. Herein, we put forth mechanistic evidence showing that clarithromycin can be utilized to prevent preterm birth and adverse neonatal outcomes in an animal model of sterile intra-amniotic inflammation.

In the current study, we explored the mechanisms whereby clarithromycin prevents preterm birth and adverse neonatal outcomes. First, we report that this macrolide interferes with the common pathway of labor by reducing the gene expression of contractility-associated proteins such as OXTR, CX43, and COX2, which are increased in preterm and term labor [104]. This finding is in line with previous in vitro demonstrations showing that clarithromycin inhibits oxytocin-induced myometrial contractility [105]. Furthermore, we have previously shown that treatment with clarithromycin prevented the premature onset of labor induced by Ureaplasma parvum [15]. Notably, in the current study, we showed that treatment with clarithromycin reduced the expression of several inflammatory mediators in the intra-uterine tissues (e.g., uterus, fetal membranes, decidua, and placenta) involved in the cascade of parturition. These data are consistent with previous demonstrations in non-reproductive tissues that clarithromycin suppresses the production and secretion of inflammatory cytokines by interfering with the AP-1 and NF-κB pathways [106, 107]. Specifically, clarithromycin suppressed NF-κB-mediated pro-inflammatory cytokine production by interfering with the mitochondrial proteins 4-nitrophenylphosphatase domain and non-neuronal synaptosomal associated protein 25-like protein homolog (NIP-SNAP)-1 and -2 [107]. Furthermore, clarithromycin can dampen inflammation by modulating the concentrations of chemokines such as IL-8 [106], which results in reduced neutrophil infiltration at the site of injury [108]. Alternatively, clarithromycin can foster an anti-inflammatory milieu by increasing suppressive cytokines such as IL-10 [109], as shown in the decidua herein, and by expanding immunosuppressive innate immune cells [e.g., myeloid-derived suppressor cell (MDSC)-like cells] [110]. Taken together, these data indicate that clarithromycin prevents preterm birth largely by interfering with the inflammatory cascade of labor in the intra-uterine maternal tissues (uterine decidua and cervix).

The strategy of using anti-inflammatory approaches to tackle prematurity has been utilized by us and others [111,112,113,114,115,116,117,118]. For example, we have shown that anti-inflammatory drugs and peptides such as MCC950 (an NLRP3 inflammasome inhibitor [119]), rosiglitazone (an anti-diabetic thiazolidinedione drug [120]), and exendin-4 [an agonist of the glucagon-like protein-1 receptor (GLP1R) [121]] prevent preterm birth induced by inflammation in mice [12,13,14, 53,54,55, 122]. Yet, such strategies are not approved for use in pregnant women. To address this need, we and others have also utilized progesterone and betamethasone, drugs approved for pregnant women, to prevent inflammation-induced preterm birth in mice [17, 52, 103, 123, 124]. Notably, betamethasone can prevent preterm birth in the animal model of sterile intra-amniotic inflammation used herein [17]. Pertinent to the latter finding, clarithromycin has been shown to be as potent as corticosteroids (e.g., prednisolone) in inhibiting the production of pro-inflammatory cytokines [125]. Therefore, the use of clarithromycin to treat inflammation-induced preterm birth is well-supported.

In the current study, we showed that treatment with clarithromycin reduced the expression of several inflammatory mediators in the placenta. This finding could be explained by previous pharmacokinetics studies showing that clarithromycin efficiently crosses the human placenta [50, 51]. Indeed, clarithromycin is more efficient than other macrolides, such as azithromycin and erythromycin, at crossing the placenta [50]. The mechanisms whereby clarithromycin reduces placental inflammation must involve the inhibition of the NF-κB pathway, as has been demonstrated in other systems [106, 107] and the uterine decidua herein. Furthermore, clinical studies reported that the placentas of patients treated with clarithromycin displayed a lesser degree of histological funisitis (acute inflammation of the umbilical cord) [102, 126]. However, we also found that treatment with clarithromycin did not reduce inflammation in the amniotic cavity, as was observed in humans [45,46,47,48]; yet, a direct comparison between animal and human studies requires careful consideration. Regardless, it is tempting to suggest that the reason why clarithromycin did not fully prevent neonatal mortality induced by HMGB1 lies within its minimal effects in the amniotic cavity in our model. In the current study, another point to consider is that we utilized concentrations of clarithromycin similar to those utilized in humans [57, 58], given that macrolides can exhibit cytotoxicity at high concentrations [127]. Together, these findings also allow us to propose that the combination of approved approaches (e.g., betamethasone and clarithromycin) may be more effective for reducing the intra-amniotic inflammatory milieu compared to clarithromycin alone. Nevertheless, further research is required to test such a proposal.

A major finding of our study is that treatment with clarithromycin dampened inflammation in the fetal tissues, namely the lung, intestine, and liver. To our knowledge, this is the first evidence showing the anti-inflammatory effects of clarithromycin in a model of sterile intra-amniotic inflammation. Similarly, previous mechanistic studies in animal models have consistently shown that macrolides, such as azithromycin, reduce Ureaplasma-induced inflammatory markers in the amniotic cavity, fetal lung, and/or fetal skin [128,129,130]. Indeed, such a decrease in the local inflammatory response has been translated to improvements in physiological parameters, such as fetal cardiac output [130]. Furthermore, clarithromycin has been successfully used to diminish inflammation in patients with lung pathologies (e.g., asthma [108, 131], bronchiectasis [132], and cystic fibrosis [133]). The protective effects of clarithromycin have also been reported in gastrointestinal diseases (e.g., Helicobacter pylori infection [134], intestinal mucositis [135], and Crohn's disease [136]). In line with the abovementioned studies, we also report that clarithromycin dampens inflammation in the fetal spleen, whose inflammatory status can serve as a marker (Doppler of the fetal splenic vein) of fetal damage induced by intra-amniotic inflammation [137]. Collectively, these data suggest that the mechanisms whereby clarithromycin improves neonatal survival include dampening of inflammation in the fetal organs. However, further mechanistic demonstrations are required to investigate whether neonates born to women treated with clarithromycin are immunocompetent.

The current study has some limitations. There is a lack of information regarding the inflammatory effects induced by HMGB1 alone in gestational tissues utilizing in vivo models. Ongoing research in our lab is investigating such effects; yet, we have previously shown that the in vitro treatment of the chorioamniotic membranes with HMGB1 drives a similar inflammatory response [42] to that observed in the current study. Thus, we surmise that the vehicle control group (HMGB1 + DMSO) would have similar results in mice injected by HMGB1 alone. Another limitation is that, for the mice utilized for tissue collection, we could not distinguish between those mice that would have delivered preterm from those that would have delivered at term. Ongoing research in our lab is also focused on establishing non-invasive approaches to monitor the progression of labor in mice and identify those that can benefit from treatments to prevent preterm birth.

Conclusions

In summary, this study provides evidence that clarithromycin can be utilized to prevent preterm birth and improve neonatal survival in the context of sterile intra-amniotic inflammation. The mechanisms whereby clarithromycin prevents preterm birth involve interference with the common cascade of parturition, which is largely governed by the uterine and cervical tissues. Furthermore, clarithromycin had strong anti-inflammatory effects in the fetal tissues, providing a possible role for this macrolide in dampening fetal inflammatory responses, which translates to improved neonatal outcomes. Collectively, these data indicate that clarithromycin can be used in cases of sterile intra-amniotic inflammation, a condition that currently lacks treatment.

Availability of data and materials

All of the data generated or analyzed during this study are included in this published article or its supporting information. Gene expression data are provided as Additional File 1.

Abbreviations

DAMP:

Damage-associated molecular pattern

DMSO:

Dimethyl sulfoxide

GLP1R:

Glucagon-like protein-1 receptor

HMGB1:

High-mobility group box-1

HSP70:

Heat-shock protein-70

IACUC:

Institutional Animal Care and Use Committee

MDSC:

Myeloid-derived suppressor cell

NLRP3:

NLR family pyrin domain-containing-3

S100B:

S100 calcium binding protein-B

References

  1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–40.

    Article  PubMed  Google Scholar 

  2. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(1):e37–46.

    Article  PubMed  Google Scholar 

  3. Guo X, Li X, Qi T, Pan Z, Zhu X, Wang H, et al. A birth population-based survey of preterm morbidity and mortality by gestational age. BMC Pregnancy Childbirth. 2021;21(1):291.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Romero R, Dey SK, Fisher SJ. Preterm labor: One syndrome, many causes. Science. 2014;345(6198):760–5.

    Article  CAS  Google Scholar 

  5. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75–84.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Romero R, Quintero R, Oyarzun E, Wu YK, Sabo V, Mazor M, et al. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. Am J Obstet Gynecol. 1988;159(3):661–6.

    Article  CAS  PubMed  Google Scholar 

  7. Gravett MG, Witkin SS, Haluska GJ, Edwards JL, Cook MJ, Novy MJ. An experimental model for intraamniotic infection and preterm labor in rhesus monkeys. Am J Obstet Gynecol. 1994;171(6):1660–7.

    Article  CAS  PubMed  Google Scholar 

  8. Romero R, Espinoza J, Gonçalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Novy MJ, Duffy L, Axthelm MK, Sadowsky DW, Witkin SS, Gravett MG, et al. Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques. Reprod Sci. 2009;16(1):56–70.

    Article  CAS  PubMed  Google Scholar 

  10. Gomez-Lopez N, Romero R, Plazyo O, Panaitescu B, Furcron AE, Miller D, et al. Intra-Amniotic Administration of HMGB1 Induces Spontaneous Preterm Labor and Birth. Am J Reprod Immunol. 2016;75(1):3–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gomez-Lopez N, Romero R, Arenas-Hernandez M, Panaitescu B, Garcia-Flores V, Mial TN, et al. Intra-amniotic administration of lipopolysaccharide induces spontaneous preterm labor and birth in the absence of a body temperature change. J Matern Fetal Neonatal Med. 2018;31(4):439–46.

    Article  CAS  PubMed  Google Scholar 

  12. Garcia-Flores V, Romero R, Miller D, Xu Y, Done B, Veerapaneni C, et al. Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4. Front Immunol. 2018;9:1291.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Faro J, Romero R, Schwenkel G, Garcia-Flores V, Arenas-Hernandez M, Leng Y, et al. Intra-amniotic inflammation induces preterm birth by activating the NLRP3 inflammasome. Biol Reprod. 2019;100(5):1290–305.

    Article  PubMed  Google Scholar 

  14. Gomez-Lopez N, Romero R, Garcia-Flores V, Leng Y, Miller D, Hassan SS, et al. Inhibition of the NLRP3 inflammasome can prevent sterile intra-amniotic inflammation, preterm labor/birth, and adverse neonatal outcomes. Biol Reprod. 2019;100(5):1306–18.

    Article  PubMed  Google Scholar 

  15. Motomura K, Romero R, Xu Y, Theis KR, Galaz J, Winters AD, et al. Intra-Amniotic Infection with Ureaplasma parvum Causes Preterm Birth and Neonatal Mortality That Are Prevented by Treatment with Clarithromycin. mBio. 2020;11(3):e00797–20.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Motomura K, Romero R, Garcia-Flores V, Leng Y, Xu Y, Galaz J, et al. The alarmin interleukin-1α causes preterm birth through the NLRP3 inflammasome. Mol Hum Reprod. 2020;26(9):712–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Galaz J, Romero R, Arenas-Hernandez M, Panaitescu B, Para R, Gomez-Lopez N. Betamethasone as a potential treatment for preterm birth associated with sterile intra-amniotic inflammation: a murine study. J Perinat Med. 2021;49(7):897–906.

    Article  CAS  PubMed  Google Scholar 

  18. Cappelletti M, Presicce P, Feiyang M, Senthamaraikannan P, Miller LA, Pellegrini M, et al. The induction of preterm labor in rhesus macaques is determined by the strength of immune response to intrauterine infection. PLoS Biol. 2021;19(9):e3001385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tantengco OAG, Menon R. Breaking Down the Barrier: The Role of Cervical Infection and Inflammation in Preterm Birth. Front Glob Womens Health. 2021;2:777643.

    Article  PubMed  Google Scholar 

  20. McCartney SA, Kapur R, Liggitt HD, Baldessari A, Coleman M, Orvis A, et al. Amniotic fluid interleukin 6 and interleukin 8 are superior predictors of fetal lung injury compared with maternal or fetal plasma cytokines or placental histopathology in a nonhuman primate model. Am J Obstet Gynecol. 2021;225(1):89 e1–e16.

    Article  CAS  Google Scholar 

  21. Motomura K, Romero R, Plazyo O, Garcia-Flores V, Gershater M, Galaz J, et al. The alarmin S100A12 causes sterile inflammation of the human chorioamniotic membranes and preterm birth and neonatal mortality in mice. Biol Reprod. 2021;105(6):1494–509.

    Article  PubMed  Google Scholar 

  22. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol. 1989;161(3):817–24.

    Article  CAS  PubMed  Google Scholar 

  23. Gibbs RS, Romero R, Hillier SL, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol. 1992;166(5):1515–28.

    Article  CAS  PubMed  Google Scholar 

  24. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001;185(5):1130–6.

    Article  CAS  PubMed  Google Scholar 

  25. Gravett MG, Novy MJ, Rosenfeld RG, Reddy AP, Jacob T, Turner M, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA. 2004;292(4):462–9.

    Article  CAS  PubMed  Google Scholar 

  26. Romero R, Miranda J, Chaiworapongsa T, Chaemsaithong P, Gotsch F, Dong Z, et al. A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes. Am J Reprod Immunol. 2014;71(4):330–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Romero R, Miranda J, Chaiworapongsa T, Korzeniewski SJ, Chaemsaithong P, Gotsch F, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol. 2014;72(5):458–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Romero R, Miranda J, Chaiworapongsa T, Chaemsaithong P, Gotsch F, Dong Z, et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. J Matern Fetal Neonatal Med. 2015;28(11):1343–59.

    Article  PubMed  Google Scholar 

  29. Romero R, Miranda J, Chaemsaithong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2015;28(12):1394–409.

    Article  PubMed  CAS  Google Scholar 

  30. Burnham P, Gomez-Lopez N, Heyang M, Cheng AP, Lenz JS, Dadhania DM, et al. Separating the signal from the noise in metagenomic cell-free DNA sequencing. Microbiome. 2020;8(1):18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10(5):399–415.

    Article  CAS  PubMed  Google Scholar 

  32. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17(4):359–65.

    Article  CAS  PubMed  Google Scholar 

  33. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  34. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429–36.

    Article  CAS  PubMed  Google Scholar 

  35. Gomez-Lopez N, Romero R. Chapter 11 - The nature of the immune response in microbial-associated and sterile intraamniotic inflammation. In: Mor G, editor. Reproductive Immunology: Academic Press; 2021. p. 207–37. https://doi.org/10.1016/B978-0-12-818508-7.00003-8.

  36. Romero R, Chaiworapongsa T, Alpay Savasan Z, Xu Y, Hussein Y, Dong Z, et al. Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1. J Matern Fetal Neonatal Med. 2011;24(12):1444–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Friel LA, Romero R, Edwin S, Nien JK, Gomez R, Chaiworapongsa T, et al. The calcium binding protein, S100B, is increased in the amniotic fluid of women with intra-amniotic infection/inflammation and preterm labor with intact or ruptured membranes. J Perinat Med. 2007;35(5):385–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Romero R, Mazor M, Brandt F, Sepulveda W, Avila C, Cotton DB, et al. Interleukin-1 alpha and interleukin-1 beta in preterm and term human parturition. Am J Reprod Immunol. 1992;27(3–4):117–23.

    Article  CAS  PubMed  Google Scholar 

  39. Romero R, Grivel JC, Tarca AL, Chaemsaithong P, Xu Z, Fitzgerald W, et al. Evidence of perturbations of the cytokine network in preterm labor. Am J Obstet Gynecol. 2015;213(6):836.e1–.e18.

    Article  CAS  Google Scholar 

  40. Chaiworapongsa T, Erez O, Kusanovic JP, Vaisbuch E, Mazaki-Tovi S, Gotsch F, et al. Amniotic fluid heat shock protein 70 concentration in histologic chorioamnionitis, term and preterm parturition. J Matern Fetal Neonatal Med. 2008;21(7):449–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Schwenkel G, Romero R, Slutsky R, Motomura K, Hsu C-D, Gomez-Lopez N. HSP70: an alarmin that does not induce high rates of preterm birth but does cause adverse neonatal outcomes. J Matern Fetal Neonatal Med. 2021;34(24):4110–8.

    Article  CAS  PubMed  Google Scholar 

  42. Plazyo O, Romero R, Unkel R, Balancio A, Mial TN, Xu Y, et al. HMGB1 Induces an Inflammatory Response in the Chorioamniotic Membranes That Is Partially Mediated by the Inflammasome. Biol Reprod. 2016;95(6):130.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Gomez-Lopez N, Romero R, Panaitescu B, Leng Y, Xu Y, Tarca AL, et al. Inflammasome activation during spontaneous preterm labor with intra-amniotic infection or sterile intra-amniotic inflammation. Am J Reprod Immunol. 2018;80(5):e13049.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Gomez-Lopez N, Motomura K, Miller D, Garcia-Flores V, Galaz J, Romero R. Inflammasomes: Their Role in Normal and Complicated Pregnancies. J Immunol. 2019;203(11):2757–69.

    Article  CAS  PubMed  Google Scholar 

  45. Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. J Matern Fetal Neonatal Med. 2016;29(17):2727–37.

    CAS  PubMed  Google Scholar 

  46. Oh KJ, Romero R, Park JY, Lee J, Conde-Agudelo A, Hong JS, et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol. 2019;221(2):140 e1–e18.

    Article  CAS  Google Scholar 

  47. Yoon BH, Romero R, Park JY, Oh KJ, Lee J, Conde-Agudelo A, et al. Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2019;221(2):142 e1–e22.

    Article  CAS  Google Scholar 

  48. Kacerovsky M, Romero R, Stepan M, Stranik J, Maly J, Pliskova L, et al. Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes. Am J Obstet Gynecol. 2020;223(1):114 e1–e20.

    Article  CAS  Google Scholar 

  49. Yeo L, Romero R, Chaiworapongsa T, Para R, Johnson J, Kmak D, et al. Resolution of acute cervical insufficiency after antibiotics in a case with amniotic fluid sludge. J Matern Fetal Neonatal Med. 2021:1–11. https://doi.org/10.1080/14767058.2021.1881477.

  50. Witt A, Sommer EM, Cichna M, Postlbauer K, Widhalm A, Gregor H, et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol. 2003;188(3):816–9.

    Article  CAS  PubMed  Google Scholar 

  51. Park HS, Ahn BJ, Jun JK. Placental transfer of clarithromycin in human pregnancies with preterm premature rupture of membranes. J Perinat Med. 2012;40(6):641–6.

    Article  CAS  PubMed  Google Scholar 

  52. Furcron AE, Romero R, Plazyo O, Unkel R, Xu Y, Hassan SS, et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface. Am J Obstet Gynecol. 2015;213(6):846.e1–.e19.

    Article  CAS  Google Scholar 

  53. St Louis D, Romero R, Plazyo O, Arenas-Hernandez M, Panaitescu B, Xu Y, et al. Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by Rosiglitazone. J Immunol. 2016;196(3):1044–59.

    Article  CAS  PubMed  Google Scholar 

  54. Xu Y, Romero R, Miller D, Kadam L, Mial TN, Plazyo O, et al. An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is Attenuated by Rosiglitazone Treatment. J Immunol. 2016;196(6):2476–91.

    Article  CAS  PubMed  Google Scholar 

  55. Gomez-Lopez N, Romero R, Arenas-Hernandez M, Schwenkel G, St Louis D, Hassan SS, et al. In vivo activation of invariant natural killer T cells induces systemic and local alterations in T-cell subsets prior to preterm birth. Clin Exp Immunol. 2017;189(2):211–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Galaz J, Romero R, Arenas-Hernandez M, Panaitescu B, Garcia-Flores V, Gomez-Lopez N. A Protocol for Evaluating Vital Signs and Maternal-Fetal Parameters Using High-Resolution Ultrasound in Pregnant Mice. STAR Protoc. 2020;1(3):100134.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Tagliabue C, Techasaensiri C, Torres JP, Katz K, Meek C, Kannan TR, et al. Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. J Antimicrob Chemother. 2011;66(10):2323–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10(25):3045–53.

    Article  CAS  PubMed  Google Scholar 

  59. Lee ACC, Blencowe H, Lawn JE. Small babies, big numbers: global estimates of preterm birth. Lancet Glob Health. 2019;7(1):e2–3.

    Article  PubMed  Google Scholar 

  60. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002;8(1):3–13.

    Article  PubMed  Google Scholar 

  61. Romero R, Espinoza J, Gonçalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med. 2006;11(5):317–26.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Lee SM, Park JW, Kim BJ, Park CW, Park JS, Jun JK, et al. Acute histologic chorioamnionitis is a risk factor for adverse neonatal outcome in late preterm birth after preterm premature rupture of membranes. PLoS ONE. 2013;8(12):e79941.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA Pediatr. 2014;168(2):137–47.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Ko HS, Cheon JY, Choi SK, Lee HW, Lee A, Park IY, et al. Placental histologic patterns and neonatal seizure, in preterm premature rupture of membrane. J Matern Fetal Neonatal Med. 2017;30(7):793–800.

    Article  PubMed  Google Scholar 

  65. Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med. 1999;341(9):660–6.

    Article  CAS  PubMed  Google Scholar 

  66. Menon R. Fetal inflammatory response at the fetomaternal interface: A requirement for labor at term and preterm. Immunol Rev. 2022. https://doi.org/10.1111/imr.13075.

  67. Fuchs AR, Fuchs F, Husslein P, Soloff MS, Fernström MJ. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science. 1982;215(4538):1396–8.

    Article  CAS  PubMed  Google Scholar 

  68. Vink JY, Qin S, Brock CO, Zork NM, Feltovich HM, Chen X, et al. A new paradigm for the role of smooth muscle cells in the human cervix. Am J Obstet Gynecol. 2016;215(4):478e1-e11.

    Article  Google Scholar 

  69. Stygar D, Wang H, Vladic YS, Ekman G, Eriksson H, Sahlin L. Increased level of matrix metalloproteinases 2 and 9 in the ripening process of the human cervix. Biol Reprod. 2002;67(3):889–94.

    Article  CAS  PubMed  Google Scholar 

  70. Vince GS, Starkey PM, Jackson MC, Sargent IL, Redman CW. Flow cytometric characterisation of cell populations in human pregnancy decidua and isolation of decidual macrophages. J Immunol Methods. 1990;132(2):181–9.

    Article  CAS  PubMed  Google Scholar 

  71. Fidel PL Jr, Romero R, Ramirez M, Cutright J, Edwin SS, LaMarche S, et al. Interleukin-1 receptor antagonist (IL-1ra) production by human amnion, chorion, and decidua. Am J Reprod Immunol. 1994;32(1):1–7.

    Article  PubMed  Google Scholar 

  72. Osman I, Young A, Ledingham MA, Thomson AJ, Jordan F, Greer IA, et al. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term. Mol Hum Reprod. 2003;9(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  73. Gomez-Lopez N, Estrada-Gutierrez G, Jimenez-Zamudio L, Vega-Sanchez R, Vadillo-Ortega F. Fetal membranes exhibit selective leukocyte chemotaxic activity during human labor. J Reprod Immunol. 2009;80(1–2):122–31.

    Article  CAS  PubMed  Google Scholar 

  74. Gomez-Lopez N, Guilbert LJ, Olson DM. Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J Leukoc Biol. 2010;88(4):625–33.

    Article  CAS  PubMed  Google Scholar 

  75. Hamilton S, Oomomian Y, Stephen G, Shynlova O, Tower CL, Garrod A, et al. Macrophages infiltrate the human and rat decidua during term and preterm labor: evidence that decidual inflammation precedes labor. Biol Reprod. 2012;86(2):39.

    Article  PubMed  CAS  Google Scholar 

  76. Gomez-Lopez N, Vega-Sanchez R, Castillo-Castrejon M, Romero R, Cubeiro-Arreola K, Vadillo-Ortega F. Evidence for a role for the adaptive immune response in human term parturition. Am J Reprod Immunol. 2013;69(3):212–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Hamilton SA, Tower CL, Jones RL. Identification of chemokines associated with the recruitment of decidual leukocytes in human labour: potential novel targets for preterm labour. PLoS ONE. 2013;8(2):e56946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Castillo-Castrejon M, Meraz-Cruz N, Gomez-Lopez N, Flores-Pliego A, Beltran-Montoya J, Viveros-Alcaraz M, et al. Choriodecidual cells from term human pregnancies show distinctive functional properties related to the induction of labor. Am J Reprod Immunol. 2014;71(1):86–93.

    Article  CAS  PubMed  Google Scholar 

  79. Allport VC, Pieber D, Slater DM, Newton R, White JO, Bennett PR. Human labour is associated with nuclear factor-kappaB activity which mediates cyclo-oxygenase-2 expression and is involved with the “functional progesterone withdrawal.” Mol Hum Reprod. 2001;7(6):581–6.

    Article  CAS  PubMed  Google Scholar 

  80. Havelock JC, Keller P, Muleba N, Mayhew BA, Casey BM, Rainey WE, et al. Human myometrial gene expression before and during parturition. Biol Reprod. 2005;72(3):707–19.

    Article  CAS  PubMed  Google Scholar 

  81. Phillips RJ, Fortier MA, Lopez BA. Prostaglandin pathway gene expression in human placenta, amnion and choriodecidua is differentially affected by preterm and term labour and by uterine inflammation. BMC Pregnancy Childbirth. 2014;14:241.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Mendelson CR, Gao L, Montalbano AP. Multifactorial Regulation of Myometrial Contractility During Pregnancy and Parturition. Front Endocrinol (Lausanne). 2019;10:714.

    Article  Google Scholar 

  83. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015;213(4 Suppl):S29–52.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Been JV, Lievense S, Zimmermann LJ, Kramer BW, Wolfs TG. Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review and meta-analysis. J Pediatr. 2013;162(2):236–42 e2.

    Article  PubMed  Google Scholar 

  85. Oh KJ, Park JY, Lee J, Hong JS, Romero R, Yoon BH. The combined exposure to intra-amniotic inflammation and neonatal respiratory distress syndrome increases the risk of intraventricular hemorrhage in preterm neonates. J Perinat Med. 2018;46(1):9–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Venkatesh KK, Jackson W, Hughes BL, Laughon MM, Thorp JM, Stamilio DM. Association of chorioamnionitis and its duration with neonatal morbidity and mortality. J Perinatol. 2019;39(5):673–82.

    Article  PubMed  Google Scholar 

  87. Christiaens I, Zaragoza DB, Guilbert L, Robertson SA, Mitchell BF, Olson DM. Inflammatory processes in preterm and term parturition. J Reprod Immunol. 2008;79(1):50–7.

    Article  CAS  PubMed  Google Scholar 

  88. Robertson SA, Christiaens I, Dorian CL, Zaragoza DB, Care AS, Banks AM, et al. Interleukin-6 is an essential determinant of on-time parturition in the mouse. Endocrinology. 2010;151(8):3996–4006.

    Article  CAS  PubMed  Google Scholar 

  89. Gomez-Lopez N, Olson DM, Robertson SA. Interleukin-6 controls uterine Th9 cells and CD8(+) T regulatory cells to accelerate parturition in mice. Immunol Cell Biol. 2016;94(1):79–89.

    Article  CAS  PubMed  Google Scholar 

  90. Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks’ gestational age. Pediatrics. 2010;126(1):115–28.

    Article  PubMed  Google Scholar 

  91. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443–56.

    Article  PubMed  Google Scholar 

  92. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics. 2004;113(4 Suppl):1097–106.

    Article  PubMed  Google Scholar 

  94. Hoeffel G, Ginhoux F. Fetal monocytes and the origins of tissue-resident macrophages. Cell Immunol. 2018;330:5–15.

    Article  CAS  PubMed  Google Scholar 

  95. Popescu DM, Botting RA, Stephenson E, Green K, Webb S, Jardine L, et al. Decoding human fetal liver haematopoiesis. Nature. 2019;574(7778):365–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Murphy K, Weaver C. Janeway’s Immunobiology. 2017.

    Google Scholar 

  97. Michaëlsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses in the developing human fetus. J Immunol. 2006;176(10):5741–8.

    Article  PubMed  Google Scholar 

  98. Rosado MM, Aranburu A, Capolunghi F, Giorda E, Cascioli S, Cenci F, et al. From the fetal liver to spleen and gut: the highway to natural antibody. Mucosal Immunol. 2009;2(4):351–61.

    Article  CAS  PubMed  Google Scholar 

  99. Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev. 2007;65(12 Pt 2):S194-202.

    Article  PubMed  Google Scholar 

  100. Bastek JA, Gomez LM, Elovitz MA. The role of inflammation and infection in preterm birth. Clin Perinatol. 2011;38(3):385–406.

    Article  PubMed  Google Scholar 

  101. Gravett MG. Successful treatment of intraamniotic infection/inflammation: a paradigm shift. Am J Obstet Gynecol. 2019;221(2):83–5.

    Article  PubMed  Google Scholar 

  102. Lee J, Romero R, Kim SM, Chaemsaithong P, Park CW, Park JS, et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. J Matern Fetal Neonatal Med. 2016;29(5):707–20.

    Article  PubMed  Google Scholar 

  103. Arenas-Hernandez M, Romero R, Xu Y, Panaitescu B, Garcia-Flores V, Miller D, et al. Effector and Activated T Cells Induce Preterm Labor and Birth That Is Prevented by Treatment with Progesterone. J Immunol. 2019;202(9):2585–608.

    Article  CAS  PubMed  Google Scholar 

  104. Cook JL, Zaragoza DB, Sung DH, Olson DM. Expression of myometrial activation and stimulation genes in a mouse model of preterm labor: myometrial activation, stimulation, and preterm labor. Endocrinology. 2000;141(5):1718–28.

    Article  CAS  PubMed  Google Scholar 

  105. Celik H, Ayar A. Clarithromycin inhibits myometrial contractions in isolated human myometrium independent of stimulus. Physiol Res. 2002;51(3):239–45.

    CAS  PubMed  Google Scholar 

  106. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother. 2002;49(5):745–55.

    Article  CAS  PubMed  Google Scholar 

  107. Yamamoto S, Ogasawara N, Yamamoto K, Uemura C, Takaya Y, Shiraishi T, et al. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-kappaB-mediated cytokine production. Biochem Biophys Res Commun. 2017;483(3):911–6.

    Article  CAS  PubMed  Google Scholar 

  108. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.

    Article  CAS  PubMed  Google Scholar 

  109. Umezawa M, Tanaka N, Takeda K, Ihara T, Sugamata M. Clarithromycin and telithromycin increases interleukin-10 expression in the rat endometriosis model. Cytokine. 2011;55(3):339–42.

    Article  CAS  PubMed  Google Scholar 

  110. Namkoong H, Ishii M, Fujii H, Yagi K, Asami T, Asakura T, et al. Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. PLoS Pathog. 2018;14(4):e1006955.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Romero R, Tartakovsky B. The natural interleukin-1 receptor antagonist prevents interleukin-1-induced preterm delivery in mice. Am J Obstet Gynecol. 1992;167(4 Pt 1):1041–5.

    Article  CAS  PubMed  Google Scholar 

  112. Sadowsky DW, Novy MJ, Witkin SS, Gravett MG. Dexamethasone or interleukin-10 blocks interleukin-1beta-induced uterine contractions in pregnant rhesus monkeys. Am J Obstet Gynecol. 2003;188(1):252–63.

    Article  CAS  PubMed  Google Scholar 

  113. Shynlova O, Dorogin A, Li Y, Lye S. Inhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice. J Cell Mol Med. 2014;18(9):1816–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Ng PY, Ireland DJ, Keelan JA. Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth. Front Immunol. 2015;6:166.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Nadeau-Vallee M, Quiniou C, Palacios J, Hou X, Erfani A, Madaan A, et al. Novel Noncompetitive IL-1 Receptor-Biased Ligand Prevents Infection- and Inflammation-Induced Preterm Birth. J Immunol. 2015;195(7):3402–15.

    Article  CAS  PubMed  Google Scholar 

  116. Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, et al. OBE022, an Oral and Selective Prostaglandin F2alpha Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. J Pharmacol Exp Ther. 2018;366(2):349–64.

    Article  CAS  PubMed  Google Scholar 

  117. Wahid HH, Chin PY, Sharkey DJ, Diener KR, Hutchinson MR, Rice KC, et al. Toll-Like Receptor-4 Antagonist (+)-Naltrexone Protects Against Carbamyl-Platelet Activating Factor (cPAF)-Induced Preterm Labor in Mice. Am J Pathol. 2020;190(5):1030–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Coleman M, Orvis A, Wu TY, Dacanay M, Merillat S, Ogle J, et al. A Broad Spectrum Chemokine Inhibitor Prevents Preterm Labor but Not Microbial Invasion of the Amniotic Cavity or Neonatal Morbidity in a Non-human Primate Model. Front Immunol. 2020;11:770.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57(6):921–32.

    Article  CAS  PubMed  Google Scholar 

  121. Davidson MB, Bate G, Kirkpatrick P. Exenatide. Nat Rev Drug Discov. 2005;4(9):713–4.

    Article  CAS  PubMed  Google Scholar 

  122. Kadam L, Gomez-Lopez N, Mial TN, Kohan-Ghadr HR, Drewlo S. Rosiglitazone Regulates TLR4 and Rescues HO-1 and NRF2 Expression in Myometrial and Decidual Macrophages in Inflammation-Induced Preterm Birth. Reprod Sci. 2017;24(12):1590–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Elovitz MA, Mrinalini C. The use of progestational agents for preterm birth: lessons from a mouse model. Am J Obstet Gynecol. 2006;195(4):1004–10.

    Article  CAS  PubMed  Google Scholar 

  124. Shynlova O, Nadeem L, Dorogin A, Mesiano S, Lye SJ. The selective progesterone receptor modulator-promegestone-delays term parturition and prevents systemic inflammation-mediated preterm birth in mice. Am J Obstet Gynecol. 2021;226(2):249.e1–249.e21.

    Article  CAS  Google Scholar 

  125. Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope. 2002;112(10):1827–30.

    Article  CAS  PubMed  Google Scholar 

  126. Kwak HM, Shin MY, Cha HH, Choi SJ, Lee JH, Kim JS, et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. Placenta. 2013;34(4):346–52.

    Article  CAS  PubMed  Google Scholar 

  127. Rao GN, Giles HD, Rogers TS, Hoberman AM, Wolfe GW, Wang Y, et al. NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3′-Azido-3′-deoxythymidine (AZT) and Rifabutin Combinations (CAS Nos. 30516-87-1 and 7255-06-09) Administered by Gavage to Swiss (CD-1®) Mice. Research Triangle Park: National Institute of Environmental Health Sciences; 2000.

  128. Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol. 2012;207(6):475 e1–e14.

    Article  CAS  Google Scholar 

  129. Miura Y, Payne MS, Keelan JA, Noe A, Carter S, Watts R, et al. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother. 2014;58(9):5413–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Kelleher MA, Lee JY, Roberts VHJ, Novak CM, Baschat AA, Morgan TK, et al. Maternal azithromycin therapy for Ureaplasma parvum intraamniotic infection improves fetal hemodynamics in a nonhuman primate model. Am J Obstet Gynecol. 2020;223(4):578 e1–e11.

    Article  CAS  Google Scholar 

  131. Fonseca-Aten M, Okada PJ, Bowlware KL, Chavez-Bueno S, Mejias A, Rios AM, et al. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;97(4):457–63.

    Article  CAS  PubMed  Google Scholar 

  132. Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49–55.

    Article  CAS  PubMed  Google Scholar 

  133. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004;13(2):111–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–39.

    Article  PubMed  Google Scholar 

  135. Woo PC, Ng WF, Leung HC, Tsoi HW, Yuen KY. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. Pharmacol Res. 2000;41(5):527–32.

    Article  CAS  PubMed  Google Scholar 

  136. Inoue S, Nakase H, Matsuura M, Ueno S, Uza N, Kitamura H, et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn’s disease. J Gastroenterol Hepatol. 2007;22(7):984–8.

    Article  CAS  PubMed  Google Scholar 

  137. Musilova I, Kacerovsky M, Hornychova H, Kostal M, Jacobsson B. Pulsation of the fetal splenic vein–a potential ultrasound marker of histological chorioamnionitis and funisitis in women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 2012;91(9):1119–23.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Rona Wang, Gregorio Martinez III, and Chengrui Zou for their help in carrying out some of the experiments and Derek Miller for his helpful feedback on the manuscript.

Funding

This research was supported by the Perinatology Research Branch, Division of Obstetrics and Maternal–Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS) under Contract No. HHSN275201300006C (R.R.). This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health (N.G.-L.). R.R. has contributed to this work as part of his official duties as an employee of the United States Federal Government. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author information

Authors and Affiliations

  1. Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD, 20892, and Detroit, MI, 48201, USA

    Jose Galaz, Roberto Romero, Marcia Arenas-Hernandez, Marcelo Farias-Jofre, Kenichiro Motomura, Zhenjie Liu, Naoki Kawahara, Catherine Demery-Poulos, Tzu Ning Liu, Justin Padron, Bogdan Panaitescu & Nardhy Gomez-Lopez

  2. Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Jose Galaz, Marcia Arenas-Hernandez, Marcelo Farias-Jofre, Kenichiro Motomura, Zhenjie Liu, Naoki Kawahara, Catherine Demery-Poulos, Tzu Ning Liu, Justin Padron, Bogdan Panaitescu & Nardhy Gomez-Lopez

  3. Division of Obstetrics and Gynecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Catolica de Chile, 8330024, Santiago, Chile

    Jose Galaz & Marcelo Farias-Jofre

  4. Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA

    Roberto Romero

  5. Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, 48824, USA

    Roberto Romero

  6. Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA

    Roberto Romero

  7. Detroit Medical Center, Detroit, MI, 48201, USA

    Roberto Romero

  8. Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Nardhy Gomez-Lopez

Authors
  1. Jose Galaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcia Arenas-Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcelo Farias-Jofre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichiro Motomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhenjie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoki Kawahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Catherine Demery-Poulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tzu Ning Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Justin Padron
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bogdan Panaitescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nardhy Gomez-Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data: J.G., R.R., M.A.-H., and N.G.-L. Drafting the article or revising it critically for important intellectual content: J.G., M.F.-J., K.M., Z.L., N.K., C.D.-P., T.N.L., J.P., B.P., and N.G.-L. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Roberto Romero or Nardhy Gomez-Lopez.

Ethics declarations

Ethics approval and consent to paricipate

All experiments and procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Wayne State University (Protocol No. 18–03-0584 and 21–04-3506). The methods are reported in accordance with ARRIVE guidelines for the reporting of animal experiments. All animal experimental protocols have been carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

 RT-qPCR gene expression data. -ΔCT values for gene expression in the maternal and fetal tissues from mice treated with clarithromycin (CLR) or DMSO (vehicle control) reported in this study.

Additional file 2:

 Table S1. List of TaqMan® gene expression assays utilized for RT-qPCR. 

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galaz, J., Romero, R., Arenas-Hernandez, M. et al. Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice. BMC Pregnancy Childbirth 22, 503 (2022). https://doi.org/10.1186/s12884-022-04764-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12884-022-04764-2

Keywords

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us